Precision BioSciences, Inc. (DTIL)
6.67
0.00 (0.00%)
USD |
NASDAQ |
Sep 18, 16:00
6.66
-0.01
(-0.15%)
Pre-Market: 20:00
Precision BioSciences Enterprise Value : 116.86M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 116.86M |
| September 17, 2026 | 116.86M |
| September 16, 2026 | 115.81M |
| September 15, 2026 | 115.28M |
| September 14, 2026 | 121.89M |
| September 11, 2026 | 130.08M |
| September 10, 2026 | 131.93M |
| September 09, 2026 | 132.20M |
| September 08, 2026 | 136.16M |
| September 04, 2026 | 138.01M |
| September 03, 2026 | 135.37M |
| September 02, 2026 | 137.48M |
| September 01, 2026 | 142.50M |
| August 31, 2026 | 142.50M |
| August 28, 2026 | 146.21M |
| August 27, 2026 | 162.59M |
| August 26, 2026 | 164.97M |
| August 25, 2026 | 166.56M |
| August 24, 2026 | 163.92M |
| August 21, 2026 | 174.49M |
| August 20, 2026 | 171.05M |
| August 19, 2026 | 165.24M |
| August 18, 2026 | 158.10M |
| August 17, 2026 | 136.16M |
| August 14, 2026 | 136.95M |
| Date | Value |
|---|---|
| August 13, 2026 | 133.52M |
| August 12, 2026 | 136.69M |
| August 11, 2026 | 139.07M |
| August 10, 2026 | 137.75M |
| August 07, 2026 | 138.54M |
| August 06, 2026 | 136.69M |
| August 05, 2026 | 138.01M |
| August 04, 2026 | 132.99M |
| August 03, 2026 | 127.17M |
| July 31, 2026 | 125.32M |
| July 30, 2026 | 125.59M |
| July 29, 2026 | 122.68M |
| July 28, 2026 | 130.08M |
| July 27, 2026 | 132.20M |
| July 24, 2026 | 133.25M |
| July 23, 2026 | 134.31M |
| July 22, 2026 | 134.05M |
| July 21, 2026 | 141.98M |
| July 20, 2026 | 135.10M |
| July 17, 2026 | 148.58M |
| July 16, 2026 | 160.48M |
| July 15, 2026 | 173.43M |
| July 14, 2026 | 167.35M |
| July 13, 2026 | 167.62M |
| July 10, 2026 | 172.11M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 251.80B |
| 4D Molecular Therapeutics, Inc. | 518.24M |
| Agenus, Inc. | 599.19M |
| Anika Therapeutics, Inc. | 265.34M |
| BioCryst Pharmaceuticals, Inc. | 2.699B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.65M |
| Total Expenses (Quarterly) | 32.65M |
| EPS Diluted (Quarterly) | -1.263 |
| Earnings Yield | -42.72% |
| Normalized Earnings Yield | -38.26 |